查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004116

增溶輔料市場：依類型、功能、給藥途徑、原料、劑型、劑型及應用分類－2026-2032年全球市場預測

Solubility Enhancement Excipients Market by Type, Functionality, Route of Administration, Source, Form, Dosage Form, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，增溶添加劑市場價值將達到 39.7 億美元，到 2026 年將成長到 42.2 億美元，到 2032 年將達到 61.9 億美元，複合年成長率為 6.52%。

主要市場統計數據
基準年 2025 39.7億美元
預計年份：2026年 42.2億美元
預測年份 2032 61.9億美元
複合年成長率 (%) 6.52%

引言：增溶輔料的戰略重要性

隨著研發人員努力將有前景的活性成分轉化為安全、穩定且具有商業性可行性的劑型，增溶輔料在藥物研發、營養補充劑配方和個人保健產品中發揮著日益重要的作用。這些輔料如同“實現目標的鑰匙”，能夠提高溶解速率、增加表觀溶解度，並緩解那些原本會阻礙生物利用度或生產過程的配方難題。隨著分子複雜性的增加和難溶性候選物質的增多，輔料的選擇和設計正從主要依賴經驗的方法轉向與藥物發現和臨床開發活動緊密結合的策略性方法。

一項變革性的變化，重新定義了用於提高溶解度的添加劑的前景。

增溶劑領域正經歷一系列變革，這些變革正在重塑研發實踐、供應商關係以及終端用戶的期望。分子藥物發現的進步導致越來越多的候選分子水溶性降低，催生了對能夠可靠提高生物有效性且不影響穩定性或安全性的先進增溶劑解決方案的需求。同時，數位建模和In Silico預測工具的成熟使得製劑研發人員能夠在研發週期的早期階段就對增溶劑進行優先排序和策略制定，從而減少迭代次數並縮短臨床試驗時間。

2025年美國關稅對原物料、供應鏈成本及策略採購決策的累積影響

近期關稅措施和貿易政策調整引發了依賴進口添加劑、中間體和加工助劑的企業的實際擔憂。 2025年實施的各項變化累積，導致某些原料的到貨成本上升，價格波動，並促使企業重新評估供應商的佈局。對於許多配方研發人員和採購團隊而言，最直接的影響是重新關注「服務成本」的計算，更加重視關稅分類、原料產地以及在適用情況下支持優惠貿易待遇的文件。

關鍵細分洞察，揭示技術選擇、功能需求和特定應用優先順序。

按類型對增溶添加劑市場進行細分，可以發現具有不同性能和監管特性的多種技術家族。環糊精仍然是分子錯合形成的主要選擇，並根據空腔大小和客體親和性進一步分為α、BETA和γ亞型。這些特性會影響其與低分子量化合物和胜肽類候選物的相容性。親水性聚合物，例如羥丙基甲基纖維素、聚乙二醇、聚乙烯醇和聚乙烯吡咯烷酮，具有基質形成和抑制沉澱的功能，其選擇基於分子量、黏度和與活性成分的相互作用。親油性添加劑，包括脂肪酸、卵磷脂和某些界面活性劑，可以促進脂質遞送系統的構建，並提高親油性活性成分的膜滲透性。固體分散劑，例如麥芽糊精、甘露醇和山梨醇，支持非晶質分散策略，可穩定高能量形式並提高溶解速率。界面活性劑作為一類補充物質，可調節界面性質，並在自乳化藥物傳遞系統中發揮關鍵作用。

區域重點：重點關注地理因素、監管差異和供應鏈實際情況。

在美洲，創新主導的需求與成熟的生產能力緊密交織，使得製劑科學家往往優先考慮那些監管記錄清晰、供應鏈可擴展的輔料。該地區先進的合約研發生產機構（CDMO）的聚集，促進了製劑和製程開發團隊之間的快速迭代，從而支持了在複雜的口服和注射製劑中採用特種聚合物和環糊精。同時，採購慣例往往著重於品質認證和供應商資格要求，這會影響供應商的選擇和長期合約的簽訂。

主要企業洞察：競爭定位、創新重點與策略能力詳情

食品添加劑行業的主要企業透過整合深厚的技術專長、生產規模以及提供客製化服務的能力來脫穎而出，從而支持合作開發和法規申報。一些供應商大力投資於應用實驗室和技術服務團隊，使其能夠與客戶合作進行預配方研究、初步試驗和法規申報。這些能力縮短了開發週期，並減少了檢驗添加劑在整個劑型中性能所需的時間。其他競爭對手則優先考慮生產的柔軟性和地理分散性，在多個地點維持生產，以減少區域供應中斷，並確保全球供應鏈的品質一致性。

為行業領導者提供將洞察轉化為競爭優勢的實用建議。

透過建造涵蓋環糊精、親水性聚合物、親油性載體、固體分散劑和界面活性劑的強大添加劑工具包，優先考慮配方柔軟性。這能夠實現整個平台方法的快速迭代，使團隊能夠選擇添加劑功能以應對特定的原料藥挑戰。投資早期整合In Silico篩檢和實驗設計，以縮短預配方週期並減少對後期配方調整的依賴，從而維持臨床試驗進度並降低開發風險。透過認證多個地理位置分散的供應商、評估關稅風險以及製定緊急時應對計畫（包括近岸外包和雙重採購），增強供應鏈韌性，以應對關鍵添加劑的需求。

本報告的技術嚴謹性、證據基礎及分析架構所依據的調查方法。

本報告整合了一手和二手研究，全面闡述了增溶添加劑領域。調查方法結合了針對配方科學家、採購經理和法規專家的專項訪談，以及對同行評審文獻和行業指南（關於添加劑的特性和安全性）的系統性回顧。報告運用資料三角驗證技術，將質性研究結果與技術文件和公開的法規先例進行比對，確保結論既反映實踐又具有科學依據。

結論：對相關人員而言，提高溶解度具有策略意義並有助於未來各項措施的整合。

在現今的添加劑市場環境中，能夠兼顧科學嚴謹性和商業性現實性的企業擁有競爭優勢。技術進步和難溶性候選物質的多樣化，已將添加劑的作用從單純的輔助材料提升為產品成功的策略要素。同時，製造流程的現代化、監管的加強以及貿易政策的演變，也增加了添加劑選擇和採購的複雜性。因此，配方策略必須從多層次的觀點進行評估，涵蓋功能性能、可製造性、供應穩定性以及法規應對力等多個方面。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：增溶輔料市場：依類型分類

  • 環糊精
    • α-環糊精
    • BETA-環糊精
    • γ-環糊精
  • 親水性聚合物
    • 羥丙基甲基纖維素（HPMC）
    • PEG（聚乙二醇）
    • 聚乙烯醇（PVA）
    • PVP（聚乙烯吡咯烷酮）
  • 親油性添加劑
    • 脂肪酸
    • 卵磷脂
    • 界面活性劑
  • 固體分散劑
    • 麥芽糊精
    • 甘露醇
    • 山梨醇
  • 界面活性劑

第9章：增溶輔料市場：功能性

  • 生物有效性增強劑
  • 控制釋放劑
  • 增溶劑
  • 穩定器

第10章：增溶輔料市場：依給藥途徑分類

  • 注射給藥
  • 口服給藥
  • 體外給藥
  • 經皮給藥

第11章：增溶輔料市場：依來源分類

  • 天然輔料
  • 合成輔料

第12章：增溶輔料市場：依劑型分類

  • 液體
  • 粉末

第13章 依劑型分類的增溶輔料市場

  • 吸入製劑
  • 注射藥物
  • 口服製劑
  • 外用製劑

第14章：增溶輔料市場：依應用領域分類

  • 化妝品和個人護理
  • 營養保健品
  • 製藥

第15章：增溶輔料市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：增溶輔料市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 增溶輔料市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國增溶輔料市場

第19章：中國增溶輔料市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ABITEC Corporation
  • Air Liquide SA
  • Ashland Global Holdings Inc.
  • BASF SE
  • Cargill, Incorporated
  • Clariant International Ltd.
  • Croda International PLC
  • DuPont de Nemours Inc.
  • Evonik Industries AG
  • FMC Corporation
  • FREUND Corporation
  • Gattefosse
  • IMCD Group
  • JRS Pharma GmbH & Co. KG
  • Kerry Group PLC
  • Lubrizol Corporation
  • Merck KGaA
  • Nippon Soda Co. Ltd.
  • Pharma Excipients International AG
  • Roquette Freres SA
  • Shin-Etsu Chemical Co., Ltd.
  • Solvay SA
  • SPI Pharma Inc.
  • The DOW Chemical Company
  • Wacker Chemie AG
Product Code: MRR-62667ADFA2A9

The Solubility Enhancement Excipients Market was valued at USD 3.97 billion in 2025 and is projected to grow to USD 4.22 billion in 2026, with a CAGR of 6.52%, reaching USD 6.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.97 billion
Estimated Year [2026] USD 4.22 billion
Forecast Year [2032] USD 6.19 billion
CAGR (%) 6.52%

Introduction Framing the Strategic Importance of Solubility Enhancement Excipients

Solubility enhancement excipients play an increasingly pivotal role across pharmaceutical development, nutraceutical formulations, and personal care products as developers seek to translate promising active ingredients into safe, stable, and commercially viable dosage forms. These excipients act as enablers: they improve dissolution rates, increase apparent solubility, and mitigate formulation challenges that otherwise impede bioavailability and manufacturability. As molecular complexity and the prevalence of poorly soluble candidates have grown, excipient selection and engineering have moved from a largely empirical step to a strategic discipline closely integrated with discovery and clinical development activities.

Over the past decade, formulation scientists have adopted a wider palette of solubility-enhancing technologies, combining traditional approaches such as surfactants and hydrophilic polymers with advanced tools like cyclodextrin complexation and engineered solid dispersion systems. This transition reflects an expanded scientific understanding of drug-excipient interactions, as well as improved analytical and process capabilities that enable targeted manipulation of solid-state properties and dissolution behavior. Consequently, excipient choices now impact not only immediate formulation performance but also downstream manufacturing scalability, regulatory pathways, and lifecycle management.

Regulatory and supply-chain considerations further elevate the strategic importance of excipient selection. Regulators increasingly scrutinize novel excipient usage and expect robust justification and characterization. Meanwhile, supply chain resilience and quality assurance have become central when sourcing specialized polymers, cyclodextrins, or lipophilic carriers. Therefore, an integrated approach that combines formulation science, regulatory foresight, and sourcing strategy is indispensable for organizations aiming to accelerate development timelines while preserving product quality and compliance.

This report provides a structured, evidence-based overview of the solubility enhancement excipients landscape. It synthesizes technical principles, competitive dynamics, and application-centric insights to support informed decision-making across R&D, manufacturing, procurement, and commercial functions. The objective is to equip leaders with actionable context that bridges laboratory choices and market outcomes, enabling formulation strategies that are both scientifically sound and commercially pragmatic.

Transformative Shifts Reshaping the Solubility Enhancement Excipients Landscape

The landscape for solubility enhancement excipients is evolving through several transformative shifts that are reshaping R&D practices, supplier relationships, and end-user expectations. Advances in molecular discovery have led to an increasing share of candidate molecules with low aqueous solubility, which in turn has amplified demand for sophisticated excipient solutions that can reliably improve bioavailability without compromising stability or safety. Concurrently, digital modeling and in silico prediction tools have matured, allowing formulators to prioritize excipients and design strategies earlier in the development cycle, thereby reducing iteration and accelerating time to clinic.

Process intensification and continuous manufacturing trends are influencing excipient selection by imposing tighter constraints on thermal stability, viscosity, and compatibility with high-throughput processing equipment. These manufacturing drivers are prompting a shift toward excipients that can deliver consistent performance under accelerated processing regimes and that facilitate scale-up from pilot to commercial lines. At the same time, regulatory expectations around excipient characterization and justification have intensified, especially for novel carriers and adjuvants; formulators must now provide more comprehensive data packages that demonstrate safety, impurity control, and functional performance.

Sustainability and supply chain resilience represent additional vectors of change. End-users and procurement teams increasingly demand transparency about excipient sourcing, environmental footprint, and long-term availability. This pressure favors suppliers that can demonstrate responsible sourcing practices, diversified production footprints, and robust quality systems. Moreover, collaboration across the value chain - from API developers to contract manufacturing organizations and excipient specialists - is becoming more common, driven by the need to integrate formulation strategies with clinical and commercial objectives.

Ultimately, these shifts are creating a hybrid environment where scientific innovation, manufacturing pragmatism, and commercial considerations intersect. Companies that align formulation science with regulatory strategy, supply chain planning, and sustainability will be better positioned to turn solubility challenges into competitive advantage.

Cumulative Impact of United States Tariffs 2025 on Raw Materials, Supply Chain Costs, and Strategic Sourcing Decisions

Recent tariff measures and trade policy adjustments have raised practical concerns for organizations that depend on internationally sourced excipients, intermediates, and processing aids. Changes introduced in 2025 have had a cumulative effect by increasing landed costs for certain raw materials, creating pricing volatility, and triggering reevaluation of supplier footprints. For many formulators and procurement teams, the immediate implication has been a renewed focus on cost-to-serve calculations, with increased attention to tariff classifications, origin of materials, and documentation that supports preferential trade treatment where applicable.

In response to tariff-driven cost pressures, some manufacturers have accelerated diversification of supplier networks and explored nearshoring options to mitigate exposure to cross-border duties and logistics disruptions. This reorientation often involves trade-offs: while nearshoring can reduce tariff burdens and lead times, it may require investment to qualify new suppliers and to ensure consistent material quality. Similarly, organizations are more frequently engaging in tariff engineering and product requalification strategies to adapt formulations or packaging in ways that alter tariff treatment without affecting therapeutic performance.

Beyond direct cost effects, tariffs have influenced inventory management and procurement cadence. Companies have adopted more robust scenario planning and buffer strategies, adjusting order quantities and delivery schedules to smooth the impact of duty fluctuations. Contract terms and supplier agreements are being revisited to include clauses that address tariff pass-through, force majeure, and long-term price stability. Additionally, regulatory documentation and customs compliance have taken on greater importance; accurate material declarations and certificates of origin are now critical to minimizing unexpected duty assessments and to securing any available exemptions.

From a strategic perspective, tariffs have also spurred more collaborative risk-sharing between buyers and suppliers. In some cases, suppliers absorb portions of tariff increases to preserve commercial relationships, while in others, buyers commit to longer-term purchase agreements in exchange for price protections. Finally, tariffs are reinforcing the value of formulation flexibility: excipient substitution, alternative delivery platforms, and process adaptations can provide levers to manage total landed cost without sacrificing product quality. Organizations that proactively integrate tariff scenario planning into development and sourcing decisions are better equipped to preserve margins and maintain supply continuity in a shifting trade environment.

Key Segmentation Insights That Illuminate Technology Choices, Functionality Demands, and Application-Specific Priorities

Segmenting the solubility enhancement excipients landscape by type reveals distinct technology families with differentiated performance and regulatory profiles. Cyclodextrins remain a core option for molecular complexation and are further differentiated into alpha, beta, and gamma subtypes that vary in cavity size and guest affinity, which influences suitability across small molecules and peptide candidates. Hydrophilic polymers such as hydroxypropyl methylcellulose, polyethylene glycol, polyvinyl alcohol, and polyvinylpyrrolidone deliver matrix-forming and precipitation-inhibition functions and are chosen according to molecular weight, viscosity, and interaction with active pharmaceutical ingredients. Lipophilic excipients, encompassing fatty acids, lecithins, and certain surfactants, facilitate lipid-based delivery systems and can improve membrane permeation for lipophilic actives. Solid dispersion agents including maltodextrin, mannitol, and sorbitol support amorphous dispersion strategies that stabilize high-energy forms and enhance dissolution rates. Surfactants, as a complementary class, modulate interfacial properties and can be pivotal in self-emulsifying drug delivery systems.

When analyzing the market by functionality, four primary performance categories emerge: agents that primarily enhance bioavailability, those that modify release kinetics, excipients that improve solubility per se, and stabilizers that preserve the physical and chemical integrity of formulations. Each functionality imposes distinct analytical and regulatory demands; for instance, bioavailability enhancers often require demonstration of consistent in vivo behavior, while stabilizers demand long-term impurity and degradation profiling. Route of administration also shapes excipient selection. Injectable modalities prioritize sterile-grade excipients with low endotoxin risk and stringent particulate control, oral delivery favors excipients compatible with high-throughput compression and encapsulation, while topical and transdermal pathways emphasize skin compatibility and permeation characteristics.

Source and form are equally consequential. Natural excipients offer marketing advantages in certain consumer-facing segments but may introduce batch variability and supply constraints, whereas synthetic excipients deliver tighter specification control and scalability. Liquid forms suit applications requiring immediate dissolution or ready-to-use parenteral formats, while powders provide flexibility for dry blending, spray-drying, or hot-melt extrusion workflows. Dosage form segmentation-spanning inhalation, injectable, oral, and topical formulations-creates distinct technical barometers for excipient performance, including aerosolizability for inhalation and sterility maintenance for injectables. Finally, application contexts in cosmetics and personal care, nutraceuticals, and pharmaceuticals each impose unique regulatory, sensory, and cost thresholds that shape which excipients are prioritized in development pipelines.

Taken together, these segmentation lenses illuminate how functional needs, delivery routes, material origins, and form factors interact to drive excipient selection. Sophisticated formulation strategies increasingly rely on hybrid approaches, combining complementary excipient classes to achieve balanced dissolution, stability, and manufacturability outcomes tailored to the intended application domain.

Key Regional Insights Highlighting Geographic Drivers, Regulatory Differences, and Supply Chain Realities

The Americas region exhibits a strong blend of innovation-driven demand and mature manufacturing capability, where formulation scientists often prioritize excipients that have clear regulatory pedigrees and scalable supply chains. In this region, close proximity to advanced contract development and manufacturing organizations encourages rapid iteration between formulation and process development teams, supporting the adoption of specialized polymers and cyclodextrins for complex oral and parenteral products. Meanwhile, procurement practices often reflect an emphasis on quality certifications and supplier qualifications, which influence supplier selection and long-term contracts.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory alignment with stringent European standards drives cautious adoption of novel excipients while creating opportunities for suppliers that can demonstrate comprehensive safety and sustainability credentials. Regulatory frameworks in this combined region place a premium on detailed excipient characterization and on environmental compliance during manufacturing. As a result, suppliers that can provide transparent sourcing information and reduced environmental footprints are favored, especially for consumer-facing segments and innovative pharmaceutical applications.

Asia-Pacific displays rapid uptake of solubility enhancement technologies driven by expanding pharmaceutical development activity and increasing local manufacturing capacity. The region combines cost-sensitive procurement with growing expertise in advanced formulation approaches, which yields a dual market for both commodity excipients and higher-performance specialty carriers. Supply chain dynamics in Asia-Pacific also influence global availability, as several key raw materials and intermediate suppliers are regionally concentrated. Consequently, changes in production capacity or export policies within this region can have outsized effects on global lead times and supplier negotiation power. Across all regions, local regulatory nuance, manufacturing capability, and supplier ecosystems interplay to shape strategic choices around excipient sourcing and formulation design.

Key Companies Insights Detailing Competitive Positioning, Innovation Focus, and Strategic Capabilities

Leading companies in the excipient landscape differentiate through a combination of deep technical expertise, manufacturing scale, and bespoke service capabilities that support co-development and regulatory submission. Some suppliers have invested heavily in application laboratories and technical service teams, enabling them to collaborate with clients on preformulation studies, pilot trials, and regulatory dossiers. These capabilities shorten development cycles and reduce the time required to validate excipient performance across targeted dosage forms. Other competitors emphasize manufacturing flexibility and geographic diversification, maintaining multi-site production to mitigate regional supply disruptions and to assure quality consistency across global supply chains.

Innovation strategies vary among key players. Certain companies focus on expanding their portfolios with next-generation polymers and modified cyclodextrins aimed at addressing specific classes of poorly soluble molecules. Others concentrate on process-centric innovations such as excipients optimized for hot-melt extrusion, spray-drying, or self-emulsifying systems. Strategic partnerships and acquisitions also play a role in capability building, enabling companies to add regulatory expertise, analytical depth, or novel chemistry platforms that complement their core excipient offerings. In addition, an increasing number of suppliers provide integrated services-ranging from formulation consultancy to stability testing and scale-up support-which further strengthens commercial relationships and creates higher switching costs for clients.

Ultimately, competitive advantage in this sector derives from the ability to offer reproducible technical performance, regulatory support, and supply reliability. Companies that align these strengths with transparent sustainability credentials and flexible commercial models are best positioned to capture long-term customer commitment and to lead collaborative development efforts.

Actionable Recommendations for Industry Leaders to Translate Insights into Competitive Advantage

Prioritize formulation flexibility by building a robust excipient toolkit that spans cyclodextrins, hydrophilic polymers, lipophilic carriers, solid dispersion agents, and surfactants, enabling rapid iteration across platform approaches and allowing teams to match excipient functionality with specific API challenges. Invest in earlier integration of in silico screening and experimental design to shorten preformulation cycles and to reduce reliance on late-stage reformulation, thereby preserving clinical timelines and lowering development risk. Strengthen supply chain resilience by qualifying multiple suppliers across geographies, assessing tariff exposure, and codifying contingency plans that include nearshoring or dual sourcing for critical excipients.

Enhance regulatory readiness by generating thorough characterization data packages for novel excipients and by engaging with regulatory authorities early when pursuing innovative carriers or formulations. Align sustainability and transparency initiatives with procurement practices to respond to buyer and regulator expectations, and to differentiate your product positioning in markets where environmental credentials influence purchasing decisions. Finally, cultivate deeper partnerships with excipient suppliers through joint development agreements and long-term commercial terms that incentivize innovation and secure supply, while negotiating clear contractual provisions for tariff pass-through and price stability to manage trade policy volatility.

Research Methodology Underpinning the Report's Technical Rigor, Evidence Base, and Analytical Framework

This report synthesizes primary and secondary research streams to construct a holistic view of the solubility enhancement excipients domain. The methodology blends targeted expert interviews with formulation scientists, procurement leads, and regulatory specialists, with a systematic review of peer-reviewed literature and industry guidance on excipient characterization and safety. Data triangulation techniques were applied to reconcile qualitative insights with technical documentation and public regulatory precedent, ensuring that conclusions reflect both practice and evidence.

Analytical frameworks included technology segmentation by excipient type and functionality, route-of-administration mapping, and application-level considerations that account for differing regulatory and sensory requirements. Supply chain analysis evaluated supplier concentration, geographic production footprints, and trade policy influences that affect material availability. To ensure rigor, assumptions and interpretations were cross-validated through stakeholder consultations, and where appropriate, scenario analysis was used to stress-test implications such as tariff changes and manufacturing shifts. The resulting synthesis aims to balance technical depth with strategic clarity to support practical decision-making across development, manufacturing, and procurement functions.

Conclusion Synthesizing Strategic Implications and Next Steps for Stakeholders Focused on Solubility Enhancement

The contemporary excipient landscape rewards organizations that combine scientific rigor with commercial pragmatism. Technological advances and a growing diversity of poorly soluble candidates have elevated the role of excipients from ancillary materials to strategic enablers of product success. Concurrently, manufacturing modernization, regulatory scrutiny, and trade policy dynamics have increased the complexity of excipient selection and sourcing. As a result, formulation strategies must now be evaluated through multilayered lenses that include functional performance, manufacturability, supply resilience, and regulatory readiness.

Going forward, stakeholders should prioritize integrated planning that aligns preformulation decisions with supplier strategies and regulatory engagement. By adopting a proactive approach to excipient qualification, by diversifying sourcing channels, and by embedding cost and tariff scenario planning into procurement processes, organizations can reduce technical risk and preserve commercial flexibility. In short, companies that systemically manage the intersection of science, supply chain, and compliance will secure clearer pathways from molecule selection to market launch and beyond.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solubility Enhancement Excipients Market, by Type

  • 8.1. Cyclodextrins
    • 8.1.1. Alpha-cyclodextrin
    • 8.1.2. Beta-cyclodextrin
    • 8.1.3. Gamma-cyclodextrin
  • 8.2. Hydrophilic Polymers
    • 8.2.1. Hydroxypropyl methylcellulose (HPMC)
    • 8.2.2. PEG (Polyethylene glycol)
    • 8.2.3. Polyvinyl alcohol (PVA)
    • 8.2.4. PVP (Polyvinylpyrrolidone)
  • 8.3. Lipophilic Excipients
    • 8.3.1. Fatty Acids
    • 8.3.2. Lecithins
    • 8.3.3. Surfactants
  • 8.4. Solid Dispersion Agents
    • 8.4.1. Maltodextrin
    • 8.4.2. Mannitol
    • 8.4.3. Sorbitol
  • 8.5. Surfactants

9. Solubility Enhancement Excipients Market, by Functionality

  • 9.1. Bioavailability Enhancers
  • 9.2. Release Modifiers
  • 9.3. Solubility Enhancers
  • 9.4. Stabilizers

10. Solubility Enhancement Excipients Market, by Route of Administration

  • 10.1. Injectable Drug Delivery
  • 10.2. Oral Drug Delivery
  • 10.3. Topical Drug Delivery
  • 10.4. Transdermal Drug Delivery

11. Solubility Enhancement Excipients Market, by Source

  • 11.1. Natural Excipients
  • 11.2. Synthetic Excipients

12. Solubility Enhancement Excipients Market, by Form

  • 12.1. Liquid
  • 12.2. Powder

13. Solubility Enhancement Excipients Market, by Dosage Form

  • 13.1. Inhalation Formulation
  • 13.2. Injectable Formulation
  • 13.3. Oral Formulation
  • 13.4. Topical Formulation

14. Solubility Enhancement Excipients Market, by Application

  • 14.1. Cosmetics & Personal Care
  • 14.2. Nutraceuticals
  • 14.3. Pharmaceuticals

15. Solubility Enhancement Excipients Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Solubility Enhancement Excipients Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Solubility Enhancement Excipients Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Solubility Enhancement Excipients Market

19. China Solubility Enhancement Excipients Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. ABITEC Corporation
  • 20.6. Air Liquide S.A.
  • 20.7. Ashland Global Holdings Inc.
  • 20.8. BASF SE
  • 20.9. Cargill, Incorporated
  • 20.10. Clariant International Ltd.
  • 20.11. Croda International PLC
  • 20.12. DuPont de Nemours Inc.
  • 20.13. Evonik Industries AG
  • 20.14. FMC Corporation
  • 20.15. FREUND Corporation
  • 20.16. Gattefosse
  • 20.17. IMCD Group
  • 20.18. JRS Pharma GmbH & Co. KG
  • 20.19. Kerry Group PLC
  • 20.20. Lubrizol Corporation
  • 20.21. Merck KGaA
  • 20.22. Nippon Soda Co. Ltd.
  • 20.23. Pharma Excipients International AG
  • 20.24. Roquette Freres SA
  • 20.25. Shin-Etsu Chemical Co., Ltd.
  • 20.26. Solvay SA
  • 20.27. SPI Pharma Inc.
  • 20.28. The DOW Chemical Company
  • 20.29. Wacker Chemie AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ALPHA-CYCLODEXTRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ALPHA-CYCLODEXTRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ALPHA-CYCLODEXTRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BETA-CYCLODEXTRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BETA-CYCLODEXTRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BETA-CYCLODEXTRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY GAMMA-CYCLODEXTRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY GAMMA-CYCLODEXTRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY GAMMA-CYCLODEXTRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE (HPMC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE (HPMC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE (HPMC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PEG (POLYETHYLENE GLYCOL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PEG (POLYETHYLENE GLYCOL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PEG (POLYETHYLENE GLYCOL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POLYVINYL ALCOHOL (PVA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POLYVINYL ALCOHOL (PVA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POLYVINYL ALCOHOL (PVA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PVP (POLYVINYLPYRROLIDONE), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PVP (POLYVINYLPYRROLIDONE), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PVP (POLYVINYLPYRROLIDONE), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FATTY ACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FATTY ACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FATTY ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LECITHINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LECITHINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LECITHINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MALTODEXTRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MALTODEXTRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MALTODEXTRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MANNITOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MANNITOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY MANNITOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SORBITOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SORBITOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SORBITOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BIOAVAILABILITY ENHANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BIOAVAILABILITY ENHANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY BIOAVAILABILITY ENHANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY RELEASE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY RELEASE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY RELEASE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLUBILITY ENHANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLUBILITY ENHANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLUBILITY ENHANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NATURAL EXCIPIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NATURAL EXCIPIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NATURAL EXCIPIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SYNTHETIC EXCIPIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SYNTHETIC EXCIPIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SYNTHETIC EXCIPIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INHALATION FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INHALATION FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INHALATION FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ORAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TOPICAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 244. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. GCC SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOLID DISPERSION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 276. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 280. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 281. G7 SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. NATO SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY CYCLODEXTRINS, 2018-2032 (USD MILLION)
  • TABLE 285. NATO SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY HYDROPHILIC POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO SOLUBILITY ENHANCEMENT EXCIPIENTS MARKET SIZE, BY LIPOPHILIC EXCIPIENTS, 2018-2032 (U